$Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study$

Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study

Abstract Background CD19 chimeric antigen receptor (CAR) T‐cell therapy is a potential treatment for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The combination of targeted therapeutic strategies, particularly bruton tyrosine kinase inhibitor zanubrutinib and programmed death‐1 inhibitor...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rong Shen, Wei‐Guo Cao, Li Wang, Ling‐Shuang Sheng, Yi‐Lun Zhang, Wen Wu, Peng‐Peng Xu, Shu Cheng, Meng‐Ke Liu, Yan Dong, Yue Wang, Xiang‐Qin Weng, Xu‐Feng Jiang, Qi Song, Hong‐Mei Yi, Lei Li, Sheng Chen, Zi‐Xun Yan, Wei‐Li Zhao
Format:	Article
Language:	English
Published:	Wiley 2025-04-01
Series:	Clinical and Translational Medicine
Subjects:	bruton tyrosine kinase inhibitor chimeric antigen receptor T‐cell therapy large B‐cell lymphoma programmed death‐1 inhibitor tumour microenvironment
Online Access:	https://doi.org/10.1002/ctm2.70310
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
by: Benjamin J. Lee, et al.
Published: (2024-10-01)

Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2
by: Min Zhang, et al.
Published: (2025-03-01)

Pityriasis lichenoides et varioliformis acuta in a patient on zanubrutinib for marginal zone lymphoma
by: Aliya Rogers, MD, et al.
Published: (2025-01-01)

Drug review: Ibrutinib
by: Parathan Karunakaran
Published: (2020-01-01)

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies
by: Tara Murty, et al.
Published: (2025-06-01)

Efficacy of individualized orelabrutinib-based regimens in relapsed or refractory central nervous system lymphoma
by: Yuchen Wu, et al.
Published: (2025-06-01)

Prognostic risk factors of pneumonia associated with COVID-19 in patients with lymphoma
by: Dan Liu, et al.
Published: (2025-01-01)

Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment
by: Laura R. Naydovich, et al.
Published: (2025-07-01)

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia
by: Raji E Joseph, et al.
Published: (2024-12-01)

Case Report: Immune checkpoint inhibitor exhibits dual benefits for a refractory lymphoma patient with disseminated mucormycosis
by: Qibei Teng, et al.
Published: (2025-07-01)

BTK inhibition in primary central nervous system lymphoma: mechanisms, clinical efficacy, and future perspectives
by: Yurou Xing, et al.
Published: (2024-12-01)

Emerging Clinical Perspectives of Immunotherapy in Triple Negative Breast Cancer: A Comprehensive Review
by: Sparshita Dey, et al.
Published: (2025-06-01)

In silico analysis of atrial fibrillation and hypertension mechanism of action secondary to ibrutinib/acalabrutinib in chronic lymphocytic leukemia
by: Raúl Córdoba, et al.
Published: (2025-07-01)

The Potential Therapeutic Role of Bruton Tyrosine Kinase Inhibition in Neurodegenerative Diseases
by: Francesco D’Egidio, et al.
Published: (2025-07-01)

Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma: A retrospective analysis
by: Jinhuan Xu, et al.
Published: (2025-01-01)

WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS
by: Michele Bibas, et al.
Published: (2024-06-01)

Ponatinib-induced eruptive squamous cell carcinomas
by: Gabrielle Moore, MBE, MSc, et al.
Published: (2025-08-01)

SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma
by: Xianglai Xu, et al.
Published: (2024-12-01)

Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
by: Anna De Lucia, et al.
Published: (2025-02-01)

Incidence Status and Factors Associated With Tyrosine Kinase Inhibitor‐Induced Hypertension in Patients With Renal Cell Carcinoma
by: Satoru Nakanishi, et al.
Published: (2025-05-01)

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia
by: Adam S Kittai, et al.
Published: (2025-01-01)

Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed/refractory B cell acute lymphoblastic leukemia
by: Wenyue Cao, et al.
Published: (2025-04-01)

AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis
by: Muriel D Brada, et al.
Published: (2025-05-01)

Adding dendritic cell-immunotherapy for post-transplant hepatocellular carcinoma recurrence
by: Wei-Chen Lee, et al.
Published: (2025-08-01)

Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk
by: Anna Ewa Wolska-Washer, et al.
Published: (2025-01-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study
by: Joohyun Hong, et al.
Published: (2024-03-01)

Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
by: Yufei Lu, et al.
Published: (2025-04-01)

Successful treatment of an elderly patient with lung squamous cell carcinoma by tislelizumab and chemotherapy: a case report with novel imaging findings
by: Lufan Xu, et al.
Published: (2025-03-01)

The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer
by: Hao-Yu Tang, et al.
Published: (2025-01-01)

Rilzabrutinib-induced transition from <i>pemphigus vulgaris</i> to <i>pemphigus foliaceous</i>: case report and review of the literature
by: Christian Ciolfi, et al.
Published: (2024-10-01)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
by: Eugenio Galli, et al.
Published: (2021-10-01)

Atypical Cystic Primary Hepatic GIST: A Case Report of Rare Presentation and Long-Term Survival
by: Mirela Claudia Rimbu, et al.
Published: (2025-07-01)

CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges
by: Yexin Zhou, et al.
Published: (2024-11-01)

Effectiveness of systemic treatments for advanced non-clear cell renal cell carcinoma: a systematic review and meta-analysis
by: Yaping Zhang, et al.
Published: (2024-12-01)

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study
by: Chang Lu, et al.
Published: (2025-07-01)

Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis
by: Shuyun Wang, et al.
Published: (2024-10-01)

A Successful Case of Vemurafenib and Rituximab for Relapsed Hairy Cell Leukemia
by: QIU Yuchong, et al.
Published: (2025-01-01)

Transformation of adenocarcinoma into small cell lung cancer as one of the mechanisms of acquired resistance to anti-EGFR tyrosine kinase inhibitors
by: O. O. Kovalov, et al.
Published: (2024-04-01)

Immune Thrombocytopenia in an Adult With X‐linked Agammaglobulinemia: A Case Report
by: Takeaki Matsunaga, et al.
Published: (2025-04-01)